Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
398 stopped studies mapped to Sarcoma and descendants · 90% state a reason
Over the 398 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06299163 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Mar 7, 2024 | Numab Therapeutics AG | Business decision | Sponsor / business decision |
| NCT04220229 | Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities | Phase 1 / Phase 2 | terminated | Jan 7, 2020 | University of Washington | Terminated due to end of funding | Funding |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | Phase 2 | terminated | Oct 3, 2022 | Telix Pharmaceuticals (Innovations) Pty Ltd | Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic… | Other (stated, no rule matched) |
| NCT04530487 | Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or… | Phase 2 | terminated | Aug 28, 2020 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT05432193 | FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry… | Phase 1 | terminated | Jun 27, 2022 | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | Business decision | Sponsor / business decision |
| NCT05269355 | A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)(SUNRISELMS) | Phase 2 / Phase 3 | terminated | Mar 8, 2022 | PTC Therapeutics | Business decision | Sponsor / business decision |
| NCT05580588 | Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or… | Phase 2 | terminated | Oct 14, 2022 | Shanghai Pharma Biotherapeutics USA Inc. | Although no safety issues with SPH4336 were identified, efficacy in liposarcoma patient was less… | Safety / toxicity |
| NCT04148378 | A Pilot Study to Explore the Role of Gut Flora in Colorectal Cancer | — | withdrawn | Nov 1, 2019 | ProgenaBiome | Company shifted focus | Sponsor / business decision |
| NCT04347122 | Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction | Phase 4 | terminated | Apr 15, 2020 | University of Kansas Medical Center | recruitment stalled | Enrollment / accrual |
| NCT01125449 | Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease | Phase 2 | withdrawn | May 18, 2010 | Situs Cancer Research Center | Awaiting response from FDA as to status of parenteral ascorbic acid manufactured by Bioniche… | Drug supply |
| NCT04579757 | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Oct 8, 2020 | Hutchmed | Study terminated by sponsor | Other (stated, no rule matched) |
| NCT03660930 | Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced… | Phase 1 / Phase 2 | terminated | Sep 7, 2018 | University of Washington | Study was terminated at completion of the Phase 1 dose escalation due to loss of financial support. | Funding |
| NCT05819827 | Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma… | — | terminated | Apr 19, 2023 | Mayo Clinic | Low/slow accrual | Enrollment / accrual |
| NCT06106633 | Pain Reduction and Ovarian Perfusion Following Uterine Fibroid Embolization(PEDD-UFE) | N/A | terminated | Oct 30, 2023 | Massachusetts General Hospital | Insufficient Enrollment | Enrollment / accrual |
| NCT04383210 | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid… | Phase 2 | terminated | May 12, 2020 | Elevation Oncology | Business decision | Sponsor / business decision |
| NCT04553692 | Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with… | Phase 1 | terminated | Sep 17, 2020 | IGM Biosciences, Inc. | Study terminated due strategic corporate pivot to focus on auto-immune indications | Sponsor / business decision |
| NCT02584647 | PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath…(PLX3397) | Phase 1 / Phase 2 | terminated | Oct 22, 2015 | Gulam Manji | Poor enrollment | Enrollment / accrual |
| NCT02100891 | Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid…(STIR) | Phase 2 | terminated | Apr 1, 2014 | Monica Thakar | 15 patients enrolled out of planned 20, terminated due to slow enrollment at end of study | Enrollment / accrual |
| NCT05166577 | Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With… | Phase 1 | terminated | Dec 22, 2021 | Viracta Therapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04965753 | FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors | Phase 1 | terminated | Jul 16, 2021 | Foghorn Therapeutics Inc. | Sponsor decision | Sponsor / business decision |
| NCT06494787 | A Phase 2 Study Using Aliya PEF Plus Pembro for Sarcoma(SOC-2320) | Phase 2 | withdrawn | Jul 10, 2024 | Sarcoma Oncology Research Center, LLC | Lack of funding | Funding |
| NCT04213794 | Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for…(TOASTIT) | Early Phase 1 | terminated | Dec 30, 2019 | Mayo Clinic | slow accrual | Enrollment / accrual |
| NCT02657005 | TK216 in Patients With Relapsed or Refractory Ewing Sarcoma | Phase 1 / Phase 2 | terminated | Jan 15, 2016 | Oncternal Therapeutics, Inc | Sponsor Decision | Sponsor / business decision |
| NCT04979442 | Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma(MANTRA) | Phase 3 | terminated | Jul 28, 2021 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT05100628 | A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue… | Phase 1 | terminated | Oct 29, 2021 | Noxopharm Limited | Slow recruitment | Enrollment / accrual |
| NCT04791228 | A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors | Phase 2 | withdrawn | Mar 10, 2021 | Children's National Research Institute | Low enrollment. | Enrollment / accrual |
| NCT05355753 | A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or… | Phase 1 | terminated | May 2, 2022 | C4 Therapeutics, Inc. | High levels of BRD9 degradation did not result in sufficient efficacy in heavily pre-treated… | Efficacy / futility |
| NCT03118037 | Transcervical Radiofrequency Ablation of Uterine Fibroids Global Registry(SAGE) | — | terminated | Apr 18, 2017 | Gynesonics | Termination due to continued lack of patient compliance | Other (stated, no rule matched) |
| NCT04996004 | A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and…(TTI-621-03) | Phase 2 | terminated | Aug 9, 2021 | Pfizer | Pfizer decided to terminate the study for administrative reasons. The termination was neither due… | Safety / toxicity |
| NCT05017103 | Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable… | Phase 2 | terminated | Aug 23, 2021 | M.D. Anderson Cancer Center | The drug sponsor stopped supporting study. | Other (stated, no rule matched) |
| NCT05228015 | Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors | Phase 1 | terminated | Feb 8, 2022 | Ikena Oncology | Sponsor strategic reasons | Sponsor / business decision |
| NCT06217536 | Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas | Phase 1 / Phase 2 | withdrawn | Jan 22, 2024 | University of California, San Francisco | Business decision | Sponsor / business decision |
| NCT03116529 | Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma(NEXIS) | Phase 1 / Phase 2 | terminated | Apr 17, 2017 | University of Maryland, Baltimore | Limited Accrual | Enrollment / accrual |
| NCT03960060 | A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid…(CAR) | Phase 1 | terminated | May 22, 2019 | Shanghai PerHum Therapeutics Co., Ltd. | Adjustment of study strategy | Sponsor / business decision |
| NCT05128786 | CCT301-38 CAR-T in Patients With Relapsed or Refractory AXL Positive Sarcomas | Phase 1 | terminated | Nov 22, 2021 | Shanghai PerHum Therapeutics Co., Ltd. | Adjustment of study strategy | Sponsor / business decision |
| NCT03240523 | A Study to Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 5) | Phase 3 | terminated | Aug 7, 2017 | Bayer | Due to a change in the development program, the study was closed prematurely. | Other (stated, no rule matched) |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | Phase 2 | terminated | Aug 19, 2021 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT03990597 | StrataXRT in Preventing Radiation Dermatitis in Pediatric Patients Undergoing Radiation… | Phase 1 | withdrawn | Jun 19, 2019 | M.D. Anderson Cancer Center | Per PI | Other (stated, no rule matched) |
| NCT03604783 | Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors | Phase 1 | terminated | Jul 27, 2018 | Sumitomo Pharma America, Inc. | Sponsor's decision to terminate further development of the program. | Sponsor / business decision |
| NCT05655598 | TAS-116 Plus Palbociclib in Breast and Rb-null Cancer | Phase 1 | withdrawn | Dec 19, 2022 | Brown University | Lack of accrual | Enrollment / accrual |
| NCT00819169 | QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors | Phase 1 / Phase 2 | terminated | Jan 8, 2009 | NantCell, Inc. | Sponsor decision - subjects rolled over to protocol 20101116 | Sponsor / business decision |
| NCT06252727 | Fluorescent Aided Resection and Evaluation of Soft Tissue Sarcomas (FLARES) | Phase 1 | withdrawn | Feb 12, 2024 | University of California, Davis | PI choice. | Other (stated, no rule matched) |
| NCT02207309 | Pazopanib Maintenance Phase II | Phase 2 | terminated | Aug 4, 2014 | Ludwig-Maximilians - University of Munich | poor recruitment | Enrollment / accrual |
| NCT04129151 | Palbociclib + Ganitumab In Ewing Sarcoma | Phase 2 | terminated | Oct 16, 2019 | Dana-Farber Cancer Institute | The study closed early due to discontinuation of ganitumab supply. | Drug supply |
| NCT06370871 | Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab… | Phase 3 | withdrawn | Apr 17, 2024 | Boehringer Ingelheim | Sponsor decision. | Sponsor / business decision |
| NCT04879979 | GIST and Memory and Attention Adaptation Training(GIST-MAAT) | N/A | terminated | May 10, 2021 | University of Pittsburgh | Slow enrollment | Enrollment / accrual |
| NCT04072393 | Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers | N/A | terminated | Aug 28, 2019 | Washington University School of Medicine | Futility | Efficacy / futility |
| NCT04656262 | Low Dose Continuous Cyclophosphamide vs Standard Doxorubicin in Advanced Sarcoma Elderly…(METROPHOLYS) | Phase 3 | terminated | Dec 7, 2020 | Istituto Oncologico Veneto IRCCS | enrollment too slow to reach the target in a reasonable time frame | Enrollment / accrual |
| NCT05869994 | Evaluation of Autologous Natural Killer Cell Activity in Primary Cancer Cell Cultures | — | withdrawn | May 23, 2023 | Sarcoma Oncology Research Center, LLC | Inactive study | Other (stated, no rule matched) |
| NCT04893018 | NT-I7 for Kaposi Sarcoma in Patients With or Without HIV | Phase 1 | terminated | May 19, 2021 | Fred Hutchinson Cancer Center | Terminated due to end of funding | Funding |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jul 23, 2025source: clinicaltrials